Selected article for: "group plus chm and plus chm"

Author: Yong-an Ye
Title: Guideline-based Chinese herbal medicine treatment plus standard care for severe coronavirus disease 2019 (G-CHAMPS): evidence from China
  • Document date: 2020_4_1
  • ID: 4as055wh_31
    Snippet: To our best knowledge, this is the first prospective randomized trial to investigate the effect of NHC-NATCM-China guideline-based CHM in patients with severe COVID-19. In this trial, the odds of a shift towards death or critically ill at 7 days after treatment was lower in the CHM plus group, at a non-significant level. The result was collaborated with the universal normalization or near normalization of leukocytes and different inflammatory mar.....
    Document: To our best knowledge, this is the first prospective randomized trial to investigate the effect of NHC-NATCM-China guideline-based CHM in patients with severe COVID-19. In this trial, the odds of a shift towards death or critically ill at 7 days after treatment was lower in the CHM plus group, at a non-significant level. The result was collaborated with the universal normalization or near normalization of leukocytes and different inflammatory markers. In a retrospective study with data of 1,099 patients with COVID-19, 5% of the patients were admitted to the ICU, 2% underwent invasive mechanical ventilation, and 1% died; whereas the composite of these endpoints occurred in 25% of the patients with severe disease (8) . In our trial, 12% of the patients with severe COVID-19 required ICU care and 5% died within 7 days. Disease severity is an important factor when considering treatment for COVID-19 and likely contributed to the differences between these two studies. An All rights reserved. No reuse allowed without permission. the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

    Search related documents:
    Co phrase search for related documents